SC
PCRX icon

Sierra Capital’s Pacira BioSciences PCRX Stock Holding History

Sierra Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Hold
12,500
– – 0.03% 194
2025
Q4 		$324K Hold
12,500
– – 0.03% 174
2025
Q3 		$322K Hold
12,500
– – 0.04% 187
2025
Q2 		$299K Buy
+12,500
New +$315K 0.03% 188

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sierra Capital's PCRX Position: Q1 2026 in Review

Sierra Capital held its Pacira BioSciences (PCRX) position steady in Q1 2026 at 12,500 shares worth $283K. The position accounts for 0.03% of the portfolio, ranked #194.

Sierra Capital first reported a position in PCRX in Q2 2025 and has held it in 4 quarters since. The position peaked at $324K in Q4 2025. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

  • Sierra Capital held 12,500 shares of Pacira BioSciences worth $283K as of Q1 2026.
  • Sierra Capital left its Pacira BioSciences share count unchanged in Q1 2026.
  • Pacira BioSciences made up 0.03% of Sierra Capital's portfolio in Q1 2026, its #194 holding.
  • Sierra Capital first reported a position in Pacira BioSciences in Q2 2025 and has held it in 4 quarters since.
  • Sierra Capital's Pacira BioSciences position peaked at $324K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Sierra Capital's 13F filing for Q1 2026, filed 15 May 2026.